Letybo vs. Xeomin: Two Different Approaches to Low-Antibody Botulinum Toxins (2026 Guide)

If you have been reading up on neurotoxins, both Letybo and Xeomin probably surfaced as Botox alternatives that lean on antibody-related selling points — and they get there from opposite directions. Letybo is a conventional 900 kDa complexed toxin whose BLESS phase-3 program reported no neutralizing antibodies. Xeomin is the “naked toxin” — a 150 kDa molecule stripped of the accessory complexing proteins that some researchers believe drive long-term antibody formation in the first place.

This guide compares the two on mechanism, onset, duration, dosing, cost, and the actual significance of the antibody story in routine cosmetic use. It is written by a clinic that carries Letybo but not Xeomin, so the recommendation section is honest about who fits which product best.

What Letybo and Xeomin Actually Are

Both are purified type A botulinum toxin and both work by the same mechanism — blocking acetylcholine release at the neuromuscular junction so the targeted muscle relaxes. The differences are in formulation chemistry and what surrounds the active toxin.

• Letybo (letibotulinumtoxinA-wlbg) — manufactured by Hugel America. FDA-approved for cosmetic glabellar lines in February 2024. It is the dominant neurotoxin in South Korea and has been used internationally for over a decade. The active 150 kDa toxin sits inside a roughly 900 kDa protein complex with human serum albumin as the stabilizer, similar in architecture to Botox.
• Xeomin (incobotulinumtoxinA) — manufactured by Merz Aesthetics. FDA-approved for cosmetic glabellar lines in 2011. It is the only U.S. botulinum toxin formulated as a “naked” 150 kDa molecule, with the accessory complexing proteins removed during manufacturing. Merz markets this as the XTRACT precision purification process.

The key concept: complexed toxins like Letybo, Botox, and Jeuveau carry surrounding non-toxin proteins that, in theory, can be recognized by the immune system over many cycles and trigger antibody formation. The naked-toxin approach behind Xeomin removes that exposure entirely. Whether this translates into clinically meaningful long-term differences for the average cosmetic patient is debated — but the underlying chemistry is genuinely different.

Onset: How Quickly Will You See Results?

This is the one place where Letybo and Xeomin diverge most visibly.

• Letybo onset: Most patients see softening at 2–3 days, with a median onset of approximately 2.8 days reported in BLESS. Peak effect lands around 14 days.
• Xeomin onset: Most patients see softening at 5–7 days, with peak effect at roughly 14 days. The published Sattler head-to-head study placed Xeomin’s onset closer to Botox’s pace than to faster-onset toxins like Dysport or Letybo.

For a patient with an event five days away, Letybo’s faster onset is a real advantage. For routine quarterly maintenance, the spread is essentially irrelevant — by the two-week mark both products are at peak and visually equivalent.

Duration: How Long Will Results Last?

Both products are studied and labeled at the same duration window.

• Letybo: Median glabellar duration of 3–4 months in the BLESS phase-3 program.
• Xeomin: Median glabellar duration of 3–4 months across multiple registration and head-to-head trials, including the often-cited Sattler comparison against Botox and Dysport.

Neither has shown a clinically meaningful duration advantage. Individual factors — metabolism, muscle mass, dose adequacy, technique, treatment history — drive duration more than the brand. If long duration is your top priority, the option to discuss is Daxxify, studied at a 6-month median in the SAKURA program.

Dosing and Unit Conversion

Letybo and Xeomin both use the same units and the same dose as Botox, which makes switching between them clean and predictable.

Per the FDA labels:

• Letybo for glabellar lines: 20 units total, divided across 5 injection sites (4 units each).
• Xeomin for glabellar lines: 20 units total, divided across 5 injection sites (4 units each).

Both use a 1:1 conversion ratio against Botox. If you were dosed 20 units of Botox last time, your injector typically uses 20 units of Letybo or Xeomin this time, in the same five-point pattern. The labels note that units are not formally interchangeable, so a competent injector confirms total dose on the day — but the math is identical in routine glabellar use. This contrasts with Dysport (2.5–3:1) or Daxxify (2:1), where switching requires recalculation. Letybo, Xeomin, and Botox are all 1:1 cousins.

Diffusion and Precision

Both have tight diffusion profiles comparable to Botox; neither shows the broader spread pattern associated with Dysport. In practice both are well-suited for focal targets like crow’s feet, lip flips, bunny lines, and chin treatment, both behave predictably in the glabellar complex without unintended spread into the lower frontalis, and neither requires the dilution adjustments some injectors make for broader-spread toxins. If you have done well on Botox in the past, both will feel familiar.

Cost: What You Will Actually Pay in 2026

Pricing for the two products is in the same ballpark, with Letybo typically positioned a bit lower on a per-unit basis.

• Letybo: roughly $9–$15 per unit. A standard 20-unit glabellar treatment lands around $200–$300.
• Xeomin: roughly $10–$15 per unit. A standard 20-unit glabellar treatment lands around $200–$300.

Because both dose 1:1 against Botox, per-unit prices translate directly into per-treatment prices. Most clinics price Xeomin slightly below Botox; Letybo is often priced more aggressively as Hugel works to establish U.S. market share. One pricing nuance: Merz operates the Xperience loyalty program for Xeomin, while Letybo’s U.S. loyalty infrastructure is still developing. If you stack multiple treatments per year, ask your clinic which programs they participate in before optimizing on sticker price alone.

Side Effects and Safety

The side effect profiles are nearly identical, because the active molecule and mechanism are the same.

Most common adverse events in the registration trials for both products:

• Headache (3–9%)
• Injection-site reactions — mild bruising, redness, transient swelling (1–5%)
• Eyelid drooping (ptosis), typically under 1% in trained hands
• Brow asymmetry, usually correctable with a small touch-up at the 2-week mark

Both carry the standard FDA boxed warning about the theoretical possibility of distant toxin spread; at the doses used for cosmetic facial treatment, this has not been a clinically meaningful concern.

The interesting comparison is long-term immunogenicity, where each product has its own argument. Letybo: Hugel’s BLESS phase-3 program reported no neutralizing antibodies across the studied population — empirical data on the conventional 900 kDa complex. Xeomin: the naked-toxin formulation removes the accessory proteins entirely, lowering the theoretical immunogenicity floor by design. For the typical cosmetic patient at standard doses, antibody formation is uncommon with either; the argument grows stronger for high-frequency, high-dose patients, those treating both cosmetic and medical indications, or those with documented resistance to other type A toxins.

Who Is the Ideal Candidate for Each?

Letybo may be the better fit if:

• You want faster onset (2–3 days) for an upcoming event
• You are price-sensitive and your clinic prices Letybo at the lower end of the range
• You want a 1:1 Botox swap with a published low-antibody track record from BLESS

Xeomin may be the better fit if:

• You specifically want the naked-toxin profile because of antibody concerns or resistance to complexed toxins
• You prefer a formulation without human serum albumin in the active component
• Your clinic carries Xeomin and you want Merz Xperience loyalty pricing

Can You Switch Between Letybo and Xeomin?

Yes. Because both dose 1:1 against Botox, switching is straightforward. A few practical notes:

• Tell your new injector which product you previously had, the dose, and roughly when.
• You cannot mix the two in the same area in the same session.
• Switching from a complexed toxin to a naked toxin does not “reset” any developing antibody response; antibody risk is cumulative across all type A toxins.
• Most patients report no perceptible difference between Letybo, Xeomin, and Botox session to session, with the exception of the onset window — patients sometimes notice Letybo kicking in a day or two earlier.